Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

NCT00129896 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Myocet
DRUG: Taxotere
DRUG: Herceptin

Sponsor

Spanish Breast Cancer Research Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]